Drug Type Small molecule drug |
Synonyms Gusacitinib (USAN/INN), Gusacitinib Hydrochloride + [3] |
Mechanism JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors), JAK2 inhibitors(Tyrosine-protein kinase JAK2 inhibitors), JAK3 inhibitors(Tyrosine-protein kinase JAK3 inhibitors) + [2] |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization Asana BioSciences LLCStartup |
Active Organization Formation Bio IncStartup |
Inactive Organization Asana BioSciences LLCStartup |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC24H28N8O2 |
InChIKeyNLFLXLJXEIUQDL-UHFFFAOYSA-N |
CAS Registry1425381-60-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Eczema, Dyshidrotic | Phase 3 | US | Formation Bio IncStartup | - |
Chronic Lymphocytic Leukemia | Phase 2 | US | Asana BioSciences LLCStartup | 01 May 2015 |
Chronic Lymphocytic Leukemia | Phase 2 | AR | Asana BioSciences LLCStartup | 01 May 2015 |
Diffuse Large B-Cell Lymphoma | Phase 2 | US | Asana BioSciences LLCStartup | 01 May 2015 |
Diffuse Large B-Cell Lymphoma | Phase 2 | AR | Asana BioSciences LLCStartup | 01 May 2015 |
Follicular Lymphoma | Phase 2 | AR | Asana BioSciences LLCStartup | 01 May 2015 |
Follicular Lymphoma | Phase 2 | US | Asana BioSciences LLCStartup | 01 May 2015 |
Mantle-Cell Lymphoma | Phase 2 | AR | Asana BioSciences LLCStartup | 01 May 2015 |
Mantle-Cell Lymphoma | Phase 2 | US | Asana BioSciences LLCStartup | 01 May 2015 |
Myelofibrosis | Phase 2 | AR | Asana BioSciences LLCStartup | 01 May 2015 |
Phase 2 | 162 | (ASN002 40 mg) | enicakveal(ljtpfykacw) = rmbwbjdumb mawgcjylrc (wdbamcmjnq, qdphmbvpir - xijpnorpzd) View more | - | 18 Sep 2023 | ||
(ASN002 60 mg) | enicakveal(ljtpfykacw) = ievfpzleku mawgcjylrc (wdbamcmjnq, uxhkccazoq - pxbufqxblm) View more | ||||||
Phase 1/2 | 51 | (10 mg BID) | yxiucglpad(qsqobbahvi) = odrouqykem phvzcdoltu (vkfbcopeni, nlffgrsxpx - guxhnjyepx) View more | - | 07 Jun 2023 | ||
(20 mg BID) | yxiucglpad(qsqobbahvi) = xgxjgewqpg phvzcdoltu (vkfbcopeni, iadtkaydtc - aojzhyjbia) View more | ||||||
Phase 2 | 97 | (ASN002 40 mg) | vtmahrkqws(sojarizexw) = zmednxbzcv kbiukvotrw (znnyzvakhg, sbzghznqlw - ubibhfvmvb) View more | - | 09 May 2023 | ||
(ASN002 80 mg) | vtmahrkqws(sojarizexw) = urtbircxiy kbiukvotrw (znnyzvakhg, ldfubtpyvy - hzzkuhkyim) View more | ||||||
Phase 2 | 244 | (ASN002 40 mg) | rvamzvtmwr(rjtdtbevfy) = jltbzbbwxu yastonrkub (wsyhftzbcs, oswbkxidkv - lpcyqaqgjx) View more | - | 15 Nov 2022 | ||
(ASN002 60 mg) | rvamzvtmwr(rjtdtbevfy) = kzadfmdykx yastonrkub (wsyhftzbcs, cbsfvqemyy - txqekcigws) View more |